Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review

References

• Dessy E, Falleni M, Braidotti P, Del Curto B, Panigalli T, Pietra GG. Unusual clear cell variant of epithelioid mesothelioma. Arch Pathol Lab Med. 2001;125:1588–1590. doi:10.1043/0003-9985(2001)125<1588:UCCVOE>2.0.CO;2.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591–1603. doi:10.1056/NEJMra050152.
   PubMed Web of Science ®Google Scholar
• Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg. 2009;1:38–48. doi:10.4240/wjgs.v1.i1.38.
   PubMedGoogle Scholar
• Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;1:27–34. doi:10.1016/j.ctrv.2014.10.007.
   Google Scholar
• Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998;82:134–140.
   PubMed Web of Science ®Google Scholar
• Morikawa A, Jordan L, Rozner R, Patil S, Boire A, Pentsova E, Seidman AD. Characteristics and outcomes of patients with breast cancer with leptomeningeal metastasis. Clin Breast Cancer. 2017;17:23–28. doi:10.1016/j.clbc.2016.07.002.
   PubMed Web of Science ®Google Scholar
• Lee S, Ahn HK, Park YH, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Park KT, Ahn JS, et al. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations. Breast Cancer Res Treat. 2011;129:809–817. doi:10.1007/s10549-011-1682-0.
   PubMed Web of Science ®Google Scholar
• Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;Suppl 4:S265–288.
   Google Scholar
• Kokkoris CP. Leptomeningeal carcinomatosis how does cancer reach the pia-arachnoid? Cancer. 1983;51:154–160. doi:10.1002/1097-0142(19830101)51:1<154::aid-cncr2820510130>3.0.co;2-k.
   PubMed Web of Science ®Google Scholar
• Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer. 2005;92:587–593. doi:10.1038/sj.bjc.6602307.
   PubMed Web of Science ®Google Scholar
• Coffin CM, Dehner LP. Mesothelial and related neoplasms in children and adolescents: a clinicopathologic and immunohistochemical analysis of eight cases. Pediatr Pathol. 1992;12:333–347.
   PubMed Web of Science ®Google Scholar
• Marchevsky AM, Wick MR. Current controversies regarding the role of asbestos exposure in the causation of malignant mesothelioma: the need for an evidence-based approach to develop medicolegal guidelines. Ann Diagn Pathol. 2003;7:321–332.
   PubMedGoogle Scholar
• Attanoos RL, Gibbs AR. Pathology of malignant mesothelioma. Histopathology. 1997;30:403–418.
   PubMed Web of Science ®Google Scholar
• Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer. 2007;7:147–154. doi:10.1038/nrc2068.
   PubMed Web of Science ®Google Scholar
• Carbone M, Pass HI, Miele L, Bocchetta M. New developments about the association of SV40 with human mesothelioma. Oncogene. 2003;22:5173–5180. doi:10.1038/sj.onc.1206552.
   PubMed Web of Science ®Google Scholar
• Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol. 2001;27:214–215. doi:10.1053/ejso.2000.1024.
   PubMedGoogle Scholar
• Kane AB. Animal models of malignant mesothelioma. Inhal Toxicol. 2006;18:1001–1004. doi:10.1080/08958370600835393.
   PubMed Web of Science ®Google Scholar
• Zachariah B, Zachariah SB, Varghese R, Balducci L. Carcinomatous meningitis: clinical manifestations and management. Int J Clin Pharmacol Ther. 1995;33:7–12.
   PubMed Web of Science ®Google Scholar
• Taillibert S, Laigle-Donadey F, Chodkiewicz C, Sanson M, Hoang-Xuan K, Delattre JY. Leptomeningeal metastases from solid malignancy: a review. J Neurooncol. 2005;75:85–99. doi:10.1007/s11060-004-8101-x.
   PubMed Web of Science ®Google Scholar
• Forman A. Leptomeningeal carcinomatosis. Am J Clin Oncol. 1990;13:536–540.
   PubMed Web of Science ®Google Scholar
• Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol. 2005;123:724–737. doi:10.1309/2h0n-vrer-pp2l-jdua.
   PubMed Web of Science ®Google Scholar
• Acherman YI, Welch LS, Bromley CM, Sugarbaker PH. Clinical presentation of peritoneal mesothelioma. Tumori. 2003;89:269–273.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, Seregni E, Oliva DG, Laterza B, Deraco M. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14:500–508. doi:10.1245/s10434-006-9192-8.
   PubMed Web of Science ®Google Scholar
• Kaplan JG, DeSouza TG, Farkash A, Shafran B, Pack D, Rehman F, Fuks J, Portenoy R. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J Neurooncol. 1990;9:225–229.
   PubMed Web of Science ®Google Scholar
• Wasserstrom WR, Glass JP, Posner JB. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer. 1982;49:759–772. doi:10.1002/1097-0142(19820215)49:4<759::aid-cncr2820490427>3.0.co;2-7.
   PubMed Web of Science ®Google Scholar
• Little JR, Dale AJ, Okazaki H. Meningeal carcinomatosis Clinical manifestations. Arch Neurol. 1974;30:138–143. doi:10.1001/archneur.1974.00490320026003.
   PubMedGoogle Scholar
• Wolfgang G, Marcus D, Ulrike S. LC: clinical syndrome in different primaries. J Neurooncol. 1998;38:103–110.
   PubMed Web of Science ®Google Scholar
• Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer. 1998;82:733–739. doi:10.1002/(sici)1097-0142(19980215)82:4<733::aid-cncr17>3.0.co;2-z.
   PubMed Web of Science ®Google Scholar
• Chase LG, Yang S, Zachar V, Yang Z, Lakshmipathy U, Bradford J, Boucher SE, Vemuri MC. Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells. Stem Cells Transl Med. 2012;1:750–758. doi:10.5966/sctm.2012-0072.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: systematic review of clinical management and biological research. J Surg Oncol. 2011;103:822–831. doi:10.1002/jso.21787.
   PubMed Web of Science ®Google Scholar
• Lorusso V, Crucitta E, Silvestris N, Guida M, Misino A, Latorre A, De Lena M. A phase I study of capecitabine in combination with vinorelbine in advanced breast cancer. Clin Breast Cancer. 2003;4:138–141.
   PubMedGoogle Scholar
• Gieschke R, Reigner B, Blesch KS, Steimer JL. Population pharmacokinetic analysis of the major metabolites of capecitabine. J Pharmacokinet Pharmacodyn. 2002;29:25–47.
   PubMed Web of Science ®Google Scholar
• Jordan JJ, Inga A, Conway K, Edmiston S, Carey LA, Wu L, Resnick MA. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation. Mol Cancer Res. 2010;8:701–716. doi:10.1158/1541-7786.MCR-09-0442.
   PubMed Web of Science ®Google Scholar
• Kunkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, Mittelbronn M, Grotzer MA, Deubzer HE, Speleman F, et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 2012;14:859–869. doi:10.1093/neuonc/nos115.
   PubMedGoogle Scholar
• Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN, Carpizo DR. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget. 2014;5:8879–8892. doi:10.18632/oncotarget.2432.
   PubMedGoogle Scholar
• Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pelle L, Barone E, Evangelista M, Guazzelli A, Boldrini L, et al. Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines. Genes Cancer. 2017;8:438–452. doi:10.18632/genesandcancer.129.
   PubMedGoogle Scholar